Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AMG 305

Bispecific antibody · Immune activation, directed at cadherin-3 (P-cadherin) (CDH3) and mesothelin (MSLN) · developed by AMGEN

Phase 1 Most advanced trial (none active)
AMGN Developer

What is AMG 305?

AMG 305 is a BiTE bispecific antibody that binds tumor cells co-expressing cadherin-3 (CDH3) and mesothelin (MSLN) and CD3 on cytotoxic T lymphocytes. By cross-linking T cells to these tumor cells, it induces a cytotoxic T-lymphocyte response against them. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
cadherin-3 (P-cadherin) (CDH3), mesothelin (MSLN)
Mechanism
Immune activation, directed at cadherin-3 (P-cadherin) (CDH3) and mesothelin (MSLN)
Pathways
T-cell cytotoxic response
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid Tumors

Other drugs acting on CDH3 / MSLN

More from AMGEN

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind AMG 305

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.